title: Clinical features of de novo CD25-positive follicular lymphoma.
abstract: CD25 expression in follicular lymphoma (FL) has not yet been investigated. Eighty-five patients with newly diagnosed FL were retrospectively evaluated. On two-color flow cytometric analysis, CD25 was detected on CD19 + and CD20 + lymphoma cells. CD25 expression in FL tended to be higher than in reactive lymphadenopathy, but was lower than in diffuse large B-cell lymphoma. Patients with CD25 + FL (n = 12) showed clinical features of elevated soluble interleukin-2 receptor (IL-2R) levels, B symptoms and an advanced age compared with CD25 - FL (n = 73). The overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) in patients with CD25 + FL were significantly inferior to those with CD25 - FL (ORR, 60 vs. 93%; 2-year PFS, 32 vs. 80.3%; 6-year OS, 47.4 vs. 85.9%, respectively). Multivariate analysis demonstrated that CD25 positivity is an independent prognostic factor for PFS and OS in FL. CD25 + FL may constitute a distinct subgroup associated with aggressiveness and an inferior prognosis.
authors.affiliation: Division of Hematology, Department of Medicine.
authors.forename: Shin-ichiro
authors.initials: S
authors.lastname: Fujiwara
authors.forename: Kazuo
authors.initials: K
authors.lastname: Muroi
authors.forename: Raine
authors.initials: R
authors.lastname: Tatara
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Matsuyama
authors.forename: Ken
authors.initials: K
authors.lastname: Ohmine
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suzuki
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Tadashi
authors.initials: T
authors.lastname: Nagai
authors.forename: Akira
authors.initials: A
authors.lastname: Tanaka
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018941:Antigens, CD19 / Q000378:metabolism; D018951:Antigens, CD20 / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016130:Immunophenotyping; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism*; D053208:Kaplan-Meier Estimate; D008206:Lymphatic Diseases / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D008224:Lymphoma, Follicular / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012189:Retrospective Studies
chemical_list: D018941:Antigens, CD19; D018951:Antigens, CD20; D053645:Interleukin-2 Receptor alpha Subunit